Abstract
Support for patients, caregivers, and families affected by mast cell disease, from healthcare providers, patient associations collaborating on an international level, and online forums, can offer key mechanisms through which disease management can be successfully enhanced. Mast cell diseases, including mastocytosis and mast cell activation syndrome (MCAS), are rarely diagnosed maladies involving aberrant cellular growth, activation, and/or function, resulting in heterogeneous symptomatology and presentation. Seen by many specialties, especially allergy/immunology, dermatology, hematology, and gastroenterology, many healthcare providers may not recognize these diseases, necessitating enhanced advocacy by specialists, patients, caregivers, and patient associations. Internationally, patient associations have allied with medical partners, government, and industry entities to help facilitate the patient’s journey, with the goals of diminishing time to diagnosis, improving care, decreasing stress, and enhancing patient/caregiver quality of life.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77(6):1261–70.
Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–25.
Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349–55.
Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin N Am. 2014;34(2):283–95.
Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564–9.
Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2(1):70–6.
Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, et al. Patient perceptions in mast cell disorders. Immunol Allergy Clin N Am. 2018;38(3):505–25.
Russell N, Jennings S, Jennings B, Slee V, Sterling L, Castells M, et al. The Mastocytosis Society survey on mast cell disorders: part 2-patient clinical experiences and beyond. J Allergy Clin Immunol Pract. 2019;7(4):1157–65.
AAAAI. Anaphylaxis Emergency Action Plan. 2018. https://www.aaaai.org/aaaai/media/medialibrary/pdf%20documents/libraries/anaphylaxis-emergency-action-plan.pdf. Accessed 25 July 2018.
Georgin-Lavialle S, Gaillard R, Moura D, Hermine O. Mastocytosis in adulthood and neuropsychiatric disorders. Transl Res. 2016;174:77–85.. e1
Bonadonna P, Pagani M, Aberer W, Bilo MB, Brockow K, Oude Elberink H, et al. Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper. Allergy. 2015;70(7):755–63.
Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology. 2014;120(3):753–9.
Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, et al. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012;124(23–24):807–14.
El Turki A, Smith H, Llewellyn C, Jones CJ. A systematic review of patients’, parents’ and healthcare professionals’ adrenaline auto-injector administration techniques. Emerg Med J. 2017;34(6):403–16.
Sanchez-Munoz L, Morgado JM, Alvarez-Twose I, Matito A, Garcia-Montero AC, Teodosio C, et al. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol. 2016;172(1):56–63.
Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137(1):35–45.
Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017;389(10069):612–20.
AAP allergy and anaphylaxis emergency plan. 2018. https://www.aap.org/en-us/Documents/AAP_Allergy_and_Anaphylaxis_Emergency_Plan.pdf. Accessed 25 July 2018.
Valent P, Akin C, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, et al. Mast cell activation syndrome: importance of consensus criteria and call for research. J Allergy Clin Immunol. 2018;142:1008.
Acknowledgments
The authors thank Jan Hempstead, Rita Barlow, Cheri Smith, Gail Barbera, Rachel Zack, Laureen LaBrash, and Jonathan Lyons for their contributions to and assistance with the preparation of this manuscript.
Disclosures
SVJ: Research Chair, The Mastocytosis Society, Inc.; VMS: Chair, Board of Directors, The Mastocytosis Society, Inc.; JSH: Co-Chair, The UK Mastocytosis Support Group; LMT: President, Associação Brasileira de Mastocitose (Brazilian Mastocytosis Association); DWM: Chair, The Australasian Mastocytosis Society; MMM: Board Member, Asociación Española de Mastocitosis y Enfermedades Relacionadas (Spanish Association for Mastocytosis and Related Diseases); SL-R: Director/President, Mastocytosis Society Canada. The authors have no additional conflicts of interest related to the topics covered in this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jennings, S.V. et al. (2020). International Support and Advocacy for Mast Cell Disease Patients and Caregivers. In: Akin, C. (eds) Mastocytosis. Springer, Cham. https://doi.org/10.1007/978-3-030-27820-5_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-27820-5_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-27822-9
Online ISBN: 978-3-030-27820-5
eBook Packages: MedicineMedicine (R0)